Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Edelris Announces Research Collaboration Agreement with Pfizer Inc.

By Edelris s.a.s. | January 31, 2017

Edelris s.a.s., a medicinal chemistry company focused on applying its Edelris Discovery Engine (EDEN) technology toward the generation of innovative small molecule leads, announced the signing of a research collaboration agreement with Pfizer Inc. 

Under the terms of the agreement, Edelris will apply its large, diverse and tractable small molecule library platform (Keymical Space) as well as its organic, high-throughput and medicinal chemistry expertise to collaborate with Pfizer towards the identification of novel leads against Pfizer-selected targets. The financial terms of the agreement were not disclosed.

“Edelris has spent the past decade charting untapped areas of biorelevant chemical space, and has developed efficient ways to mine this resource,” said Jean-Yves Ortholand, chief executive officer of Edelris. “We are excited to challenge this space containing very fresh and innovative chemical matter with some important and potentially therapeutically relevant targets selected by leaders in the pharmaceutical industry such as Pfizer.” 

Tony Wood, senior vice president and head of medicinal sciences at Pfizer said, “We look forward to working with Edelris to explore the use of their natural product-inspired technology to potentially access novel chemical leads.” 

(Source: Edelris s.a.s.)


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE